Fig. 2
a Mean observed serum TCZ concentration–time profile in patients younger than 2 years of age and in patients 2 to 17 years of age and model-predicted steady state pharmacokinetic parameters in patients younger than 2 years and in patients 2 to 17 years of age for (b) Cmin, (c) Cmax, and (d) AUC2weeks. a Data are mean ± SD. b-d Data are medians and interquartile ranges (boxes) and minimum, maximum values (whiskers). Patients weighing < 30 kg and receiving TCZ 12 mg/kg IV Q2W were included from the study in patients 2 to 17 years of age (n = 38). AUC2weeks: area under the concentration–time curve to 2 weeks; Cmax: maximum observed postinfusion serum concentration; Cmin: concentration at the end of a dosing interval; IV: intravenous; Q2W: every 2 weeks; SD: standard deviation; TCZ: tocilizumab; y: year